4D Molecular Therapeutics, Inc. (FDMT) research: valuation against peers, fundamentals over time, risk and news coverage
FDMT
4D Molecular Therapeutics, Inc.No data in this window.
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYBULLISHBiotech Coverage Wave: H.C. Wainwright Reaffirms Buys Across Pharvaris, 4D Molecular, Cytokinetics and CorMedix
H.C. Wainwright reiterated constructive ratings on four clinical and commercial-stage biotechs on the same session, citing regulatory progress at Pharvaris, a $36 target on 4D Molecular, patent-suit developments at Cytokinetics and a strong quarter at CorMedix.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.